Clinical Research of Brachytherapy in Cancer

Dear Colleagues,

Despite technological advances in external beam radiotherapy, which involve new imaging, immobilization, and dose delivery techniques, brachytherapy remains a significant method of radiotherapy due to its high conformality. Thanks to improvements in imaging techniques, applicator miniaturization, and the increasing use of new ultra-low dose rate radioactive sources, the capabilities of brachytherapy have expanded in recent years to include new indications and locations. Local treatment, including brachytherapy, is also becoming more important in the treatment of metastatic disease, where advances in systemic treatment have significantly increased survival rates. In this context, brachytherapy, also known as interventional radiotherapy, plays a particularly important role in local disease control. Combined with stereotactic radiotherapy, chemotherapy, targeted therapy, and immunotherapy, this enables metastatic disease to become a chronic condition with long-term survival and a good quality of life. Therefore, I encourage you to publish research that expands the role of brachytherapy in both existing and new indications.

We are pleased to invite you to publish articles on the different clinical indications of brachytherapy.

This Special Issue aims to present the current place of brachytherapy in various cancers, with a particular focus on combination therapy (combined with radiotherapy and/or systemic treatment) for new indications, as well as expanding and enhancing its use for existing ones. This Special Issue aims to present the current role of brachytherapy in various cancers, with a particular focus on combination therapy for new indications, as well as expanding and enhancing its use for existing ones. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

• Interventional radiotherapy—Brachytherapy—LDR, HDR.
• Oligometastatic disease and concomitant treatment.
• Immunotherapy and brachytherapy.
• Personalized treatment and brachytherapy in neoplasm.

We look forward to receiving your contributions.

Dr. Ludmiła Grzybowska-Szatkowska
Dr. Paweł Cisek
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.